China Resources Double-Crane Pharmaceutical Co Ltd - Company Profile
Powered by 
All the data and insights you need on China Resources Double-Crane Pharmaceutical Co Ltd in one report.
$295
- Save hours of research time and resources with
our up-to-date China Resources Double-Crane Pharmaceutical Co Ltd Strategy Report
- Understand China Resources Double-Crane Pharmaceutical Co Ltd position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
China Resources Double-Crane Pharmaceutical Co Ltd (CR Double-Crane), a subsidiary of China Resources Pharmaceutical Group Ltd, develops and manufactures pharmaceuticals and medical equipment. The company’s products include tablets, capsules, large-volume injections, small-volume injections, freeze-dried powder injections and granules. It also offers paints, gels, rinses and aerosol products. The company’s pharmaceutical product's therapeutic areas include hypertension, heart failure, type 2 diabetes, hypercholesterolemia, diarrhea, neonatal respiratory distress syndrome, acute renal failure, chronic renal failure, refractory heart failure, refractory edema, electrolyte disorder, acid-alkali imbalance, acute craniocerebral trauma, viral pneumonia and bronchitis, among others. It operates in China and the US. CR Double-Crane is headquartered in Beijing, China.
Headquarters
China
Address
No.1 Lize East Er Road, Wangjing, Chaoyang District, Beijing, 100102
Website
www.dcpc.com
Telephone
86 10 64398099
No of Employees
12,269
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
600062 (SHA)
Revenue (2022)
$1.4B
6.2%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
13%
(2022 vs 2021)
Market Cap*
$3.1B
Net Profit Margin (2023)
XYZ
6.4%
(2022 vs 2021)
* As of and is in US$
China Resources Double-Crane Pharmaceutical Co Ltd premium industry data and analytics
Products and Services
| Products |
|---|
| Tablets |
| Capsules |
| Large-Volume Injections |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Plans/Strategy | In February, the company announced its plans to acquire China Resources Zizhu Pharmaceutical from Beijing Pharmaceutical Group. |
| 2022 | Contracts/Agreements | In November, the company entered into an agreement with Liaoning Electric Power Central Hospital to build the first public hospital APD experience center in Liaoning Province. |
| 2022 | Contracts/Agreements | In August, the company's subsidiary China Resources Shuanghe agreed to acquire 50.11% stake in Shenzhou Biotechnology Co., Ltd. |
Competitor Comparison
| Key Parameters | China Resources Double-Crane Pharmaceutical Co Ltd | Sichuan Kelun Pharmaceutical Co Ltd | Shanghai Shyndec Pharmaceutical Co Ltd | Zhejiang Huahai Pharmaceutical Co Ltd | Kangmei Pharmaceutical Co Ltd |
|---|---|---|---|---|---|
| Headquarters | China | China | China | China | China |
| City | Beijing | Chengdu | Shanghai | Taizhou | Shenzhen |
| State/Province | Beijing | Sichuan | Shanghai | Zhejiang | Guangdong |
| No. of Employees | 12,269 | 18,422 | 11,492 | 7,682 | 6,371 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Yu Shunting | Chairman | Executive Board | 2022 | 60 |
| Lu Wenchao | Director; President | Executive Board | 2022 | 47 |
| Han Shuo | Vice President | Senior Management | 2022 | 45 |
| Man Chao | Vice President | Senior Management | 2021 | 52 |
| Yao Donghan | Vice President | Senior Management | 2023 | 50 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward